← Inovio Pharmaceuticals, Inc. (INO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Inovio Pharmaceuticals, Inc. (INO)
Pharmaceutical Preparations · market cap $129M · as of 2026-07-14
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-09 (est.)
Earnings
Pipeline
7
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Inovio Pharmaceuticals (INO) is a micro-cap biotech with a $97M market cap and 262 employees, focused on synthetic DNA-based therapeutics for cancers and infectious diseases. Its lead asset, VGX-3100, is in Phase 3 for Vulvar HSIL, with a broader pipeline spanning cervical neoplasia, glioblastoma, head and neck cancer, urothelial carcinoma, respiratory papillomatosis, and MERS. The company carries only $26.3M in cash against a ~3.7-month runway, making near-term financing a structural emergency.
The catalyst path
- 2026-11-09 (est.)Earningsimp 5/10
- 2026-12-31 (est.)Phase 2 · INO-5401imp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| INO-3107 | Phase 2 | Respiratory Papillomatosis |
| INO-4700 | Phase 2 | Middle East Respiratory Syndrome Coronavirus (MERS-CoV) |
| VGX-3100 | Phase 3 | Vulvar High Grade Squamous Intraepithelial Lesion (HSIL) |
| VGX 3100 | Phase 2 | Cervical Intraepithelial Neoplasia |
| INO-5401 | Phase 2 | Glioblastoma |
| INO-3112 | Phase 2 | Head and Neck Squamous Cell Cancer |
| INO-9012 | Phase 2 | Urothelial Carcinoma |
Price & technical context
3-month
+0.0%
6-month
+2.7%
12-month
-52.8%
52-wk range
$0.66–$2.65
vs 50-day MA
+4.6%
vs 200-day MA
-14.6%
Realized vol
97.1%
Max drawdown
-90.3%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for INO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 7 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.